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Abstract 40 
Radiation induces rapid bone loss and enhances bone resorption and RANKL expression. 41 
RANKL provides the crucial signal to induce osteoclast differentiation and plays an 42 
important role in bone resorption. However, the mechanisms of radiation-induced 43 
osteoporosis are not fully understood. Here, we show that Crif1 expression increases in bone 44 
marrow cells after radiation. Conditional Crif1 deletion in bone marrow cells causes 45 
decreases in RANKL expression and the RANKL/OPG ratio, and relieves bone loss after 46 
radiation in mice. We further demonstrated in vitro that Crif1 promotes RANKL secretion via 47 
the cAMP/PKA pathway. Moreover, protein–protein docking screening identified five 48 
compounds as Crif1 inhibitors; these compounds dramatically suppressed RANKL secretion 49 
and CREB phosphorylation when cells were exposed to forskolin. This study enriches current 50 
knowledge of the pathogenesis of osteoporosis and provides insights into potential 51 
therapeutic strategies for osteoporosis treatment. 52 
 53 
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 55 
Introduction 56 
Osteoporosis is a high-incidence disease closely associated with radiotherapy, hormonal 57 
status, age and glucocorticoid treatment. It is characterized by an imbalance in skeletal 58 
turnover with reduced bone formation and enhanced bone resorption, leading to an increased 59 
risk of bone fracture(Khosla & Hofbauer, 2017; Phetfong et al., 2016). Osteoblasts are the 60 
bone-forming cells derived from bone marrow mesenchymal stem/stromal cells (BM-MSCs) 61 
and play an important role in the regulation of bone mass. Meanwhile, osteoclasts are the 62 
principal cells capable of resorbing bone and play an essential role in bone 63 
remodelling(Rachner, Khosla, & Hofbauer, 2011). Exposure to radiation, such as 64 
radiotherapy for cancer, can cause rapid mineral loss and increase the number of osteoclasts 65 
within metabolically active, cancellous bone tissue, leading to structural deficits. However, 66 
the mechanisms of radiation-induced bone loss are not fully understood. Current treatment of 67 
osteoporosis is based mainly on inhibiting bone resorption or stimulating bone generation to 68 
increase bone mass, novel treatment strategies that have a dual mechanisms should be 69 
developed.  70 
Osteoclasts are large, multinucleated cells derived from haematopoietic progenitors of the 71 
monocyte macrophage lineage(Boyle, Simonet, & Lacey, 2003). Their differentiation is 72 
mainly regulated by macrophage colony-stimulating factor (M-CSF), RANK ligand 73 
(RANKL), and osteoprotegerin (OPG)(Teitelbaum, 2000). M-CSF is required for osteoclast 74 
survival and proliferation, but RANKL and OPG play central roles in the activation of 75 
osteoclastogenesis(Boyce & Xing, 2007). By binding to its receptor RANK (on 76 
haematopoietic progenitors), RANKL provides the crucial signal to induce osteoclast 77 
differentiation from haematopoietic progenitor cells as well as to activate mature osteoclasts. 78 
OPG is a soluble decoy receptor that can bind to RANKL and negatively regulate RANKL 79 
binding to RANK(Wada, Nakashima, Hiroshi, & Penninger, 2006). BM-MSCs, osteocytes, 80 
osteoblasts, adipocytes, and activated T and B lymphocytes are the main sources of RANKL 81 
secretion. RANKL expression is promoted by radiation, inflammation, cytokines, hormones 82 
and a number of other agents, including those that signal through cyclic adenosine 83 
monophosphate (cAMP)/protein kinase A (PKA), glycoprotein 130 (gp130) and vitamin D 84 
receptor (VDR)(Martin & Sims, 2015; Nakashima et al., 2011). 85 
Crif1 is a multifunctional protein that can interact with many proteins to induce cell 86 
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cycle arrest, modulate oxidative stress, and regulate transcriptional activity through 87 
interactions with the DNA-binding domains of transcription factors(Chen et al., 2017; Chung 88 
et al., 2003; Kang, Hong, Kim, & Bae, 2010; Park et al., 2005; Ran et al., 2014). It is also the 89 
constitutive protein of the large mitoribosomal subunit required for the synthesis and 90 
insertion of mitochondrial-encoded OxPhos polypeptides into the mitochondrial 91 
membrane(Greber et al., 2015). Crif1 deficiency in macrophages impairs mitochondrial 92 
oxidative function and causes systemic insulin resistance and adipose tissue 93 
inflammation(Jung et al., 2018). Our previous study showed that Crif1 promotes adipogenic 94 
differentiation of BM-MSCs after radiation by modulating the cAMP/PKA signalling 95 
pathway(Zhang et al., 2015). 96 
In this study, we investigated the role of Crif1 in osteoporosis after radiation. To address 97 
this question in vivo, we generated a Crif1 bone marrow-specific conditional knockout mouse 98 
model. Conditional Crif1 deletion causes decreases in RANKL expression and the 99 
RANKL/OPG ratio and reduces bone loss after radiation. In this study, we demonstrate that 100 
Crif1 promotes osteoporosis by regulating RANKL expression via the cAMP/PKA pathway. 101 
Through screening, we also identify five compounds that could effectively inhibit RANKL 102 
expression. 103 
 104 
Results 105 
Radiation induces osteoporosis in mice 106 
To confirm the extent of bone loss over the short term after irradiation, we irradiated mice 107 
with a single dose of 5 Gy, and then, 7 days later, we harvested the left femurs. Micro-CT 108 
analysis of the distal femurs of males and females at 12 weeks of age revealed significant 109 
decreases in trabecular bone volume/total volume (BV/TV) (Figures 1A and 1B), 110 
connectivity density (Conn.D) (Figure 1C), trabecular number (Tb.N*) (Figure 1D), and bone 111 
mineral density (vBMD) (Figure 1E), but also showed significant increases in trabecular 112 
spacing (Tb.Sp*) (Figure 1G) and structure model index (SMI) (Figure 1H). There was no 113 
significant difference in trabecular thickness (Tb.Th*) (Figure 1F). Haematoxylin and eosin 114 
(H&E) staining of femoral sections from irradiated mice showed significantly decreased 115 
trabecular bone compared to controls (Figure 1I). Paraffin sections of femurs showed more 116 
TRAP-positive cells in irradiated mice than in control mice (Figure 1J). These results 117 
indicated that bone resorption was enhanced after radiation and validated the model of 118 
radiation-induced osteoporosis. Moreover, RT-qPCR data revealed dramatic increases in 119 
RANKL expression (Figure 1K) and the RANKL/OPG ratio in irradiated bone marrow cells 120 
(Figure 1L). OPG expression was not affected by radiation treatment (Figure 1K).  Notably, 121 
expression of Crif1 also increased in irradiated bone marrow cells compared with control 122 
cells 7 days after irradiation (Figure 1M).  123 
Conditional Crif1 deletion from bone marrow relieves bone loss after radiation  124 
To explore the possible relationship between Crif1 and RANKL, we constructed a bone 125 
marrow cell-specific Crif1-deficient mouse model by crossing Crif
fl/fl 
mice to 126 
B6.129P2-Lyz2tm1(cre)/Nju mice to generate Lyz2Cre;Crif
fl/fl 
mice (Figure 2A) and treated 127 
the mice with a single dose of 5 Gy. RT-qPCR results demonstrated that Lyz2Cre;Crif
fl/fl 
mice 128 
had lower RANKL expression (Figure 2B) and RANKL/OPG ratio in bone marrow cells 129 
after radiation compared to Crif
fl/fl 
mice (Figure 2C). OPG expression in bone marrow cells 130 
was not affected by Crif1 deletion (Figure 2B). Therefore, we speculated that Crif1 may be 131 
involved in the regulation of RANKL expression. To further assess the effects of Crif1 132 
deletion on osteoporosis, trabecular bone parameters of femurs were evaluated by micro-CT 133 
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analysis. Conditional Crif1 deletion from bone marrow had no effect on bone mass (Figures 134 
2D-2K). Although trabecular bone volume/total volume, connectivity density and trabecular 135 
number all decreased in Crif
fl/fl 
mice and Lyz2Cre;Crif
fl/fl 
mice after radiation compared to 136 
nonirradiated mice, these three parameters were significantly higher in irradiated 137 
Lyz2Cre;Crif
fl/fl 
mice than in irradiated Crif
fl/fl 
mice (Figures 2E ,2F and 2G). Notably, 138 
trabecular spacing in Crif
fl/fl 
mice and Lyz2Cre;Crif
fl/fl 
mice both increased visibly after 139 
radiation, but the increase in Lyz2Cre;Crif
fl/fl 
mice was less than that of Crif
fl/fl 
mice after 140 
radiation treatment (Figure 2J). Furthermore, bone mineral density decreased (Figure 2H) and 141 
structural model index increased (Figure 2K) only in irradiated Crif
fl/fl 
mice compared to 142 
nonirradiated controls, while no remarkable changes in these parameters were detected 143 
between nonirradiated and irradiated Lyz2Cre;Crif
fl/fl 
mice (Figure 2H and 2K). In addition, 144 
trabecular thickness was not influenced by Crif1 deletion or radiation treatment (Figure 2I). 145 
H&E staining of paraffin sections of femurs confirmed the previously reported micro-CT 146 
data depicting the reduced loss of trabecular tissue in Lyz2Cre;Crif
fl/fl 
mice compared to 147 
Crif
fl/fl 
mice after radiation (Figure 2L). We also detected a decreased number of 148 
TRAP-positive osteoclasts in irradiated Lyz2Cre;Crif
fl/fl 
mice compared to irradiated Crif
fl/fl 
149 
mice, indicating weakened bone resorption (Figure 2M). Taken together, these data suggested 150 
that conditional Crif1 deletion could alleviate bone resorption and reduce bone loss after 151 
radiation. 152 
Overexpression of Crif1 in BM-MSCs increases RANKL secretion and the ratio of 153 
RANKL to OPG 154 
To investigate the role of Crif1 in osteoporosis in vitro, we transfected mouse BM-MSCs 155 
with a Crif1 lentiviral overexpression vector (Figure 3A). For osteoclast induction in vitro, 156 
Crif1-overexpressing BM-MSCs and RAW264.7 cells were cocultured in a 12-well transwell 157 
unit for 7 days. RT-qPCR results showed that the relative mRNA expression of RANKL and 158 
RANKL/OPG ratio both increased in Crif1-overexpressing BM-MSCs compared to controls 159 
after 7 days of coculture (Figure 3B and 3C). Concentrations of RANKL and OPG in 160 
coculture medium were also detected by ELISA. Crif1-overexpressing BM-MSCs produced 161 
high levels of RANKL compared to the control (Figure 3D), while there was no significant 162 
difference in OPG concentration between the two groups (Figure 3E). The RANKL/OPG 163 
ratio in Crif1-overexpressing BM-MSCs was higher than in the control (Figure 3F). We also 164 
detected an increased number of tartrate-resistant alkaline phosphatase (TRAP)-positive cells 165 
in RAW264.7 cells cocultured with Crif1-overexpressing BM-MSCs (Figures 3G and 3H). 166 
These data suggested that Crif1 could promote RANKL expression and may be involved in 167 
osteoclast differentiation. 168 
Crfi1 is involved in the regulation of RANKL expression after radiation 169 
To further confirm whether Crif1 played an important role in osteoporosis after radiation, we 170 
knocked out Crif1 in RAW264.7 cells and BM-MSCs (Figures 4A and 4D), respectively. 171 
Deletion of Crif1 from RAW264.7 cells did not affect RANK expression or osteoclast 172 
differentiation (Figures 4A,  4B and 4C). We previously demonstrated that Crif1 expression 173 
was upregulated after radiation(Zhang et al., 2015), and in this study, we found that RANKL 174 
expression and the RANKL/OPG ratio were also elevated after radiation (Figures 4E, 4F, 4G 175 
and 4I).  Meanwhile, more TRAP-positive cells were found in RAW264.7 cells cocultured 176 
with BM-MSCs after radiation (Figures 4J and 4K). However, knocking out Crif1 in 177 
BM-MSCs could significantly reduce RANKL expression and the RANKL/OPG ratio both 178 
before and after radiation  (Figures 4E, 4F, 4G and 4I). OPG expression was not affected by 179 
Crif1 deletion or radiation treatment (Figures 4E and 4H). Moreover, the number of 180 
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TRAP-positive cells also decreased in Crif1 knockout BM-MSCs compared to the control 181 
after 7 days of coculture (Figures 4J and 4K). These results further demonstrated that Crif1 182 
can regulate RANKL expression, especially after radiation. 183 
Crif1 mediates adipogenesis and RANKL secretion in adipocytes 184 
To determine whether Crif1 affects RANKL expression in adipocytes, BM-MSCs were 185 
grown in mouse mesenchymal stem cell adipogenic differentiation medium. Consistent with 186 
our previous research(Zhang et al., 2015), more BM-MCSs became strongly predisposed to 187 
adipogenesis (Figures 5A, 5B and 5C). Recently, it was reported that bone marrow 188 
adipocytes can secrete RANKL(Fan et al., 2017). Here, we found an obvious increase in 189 
RANKL expression and RANKL/OPG ratio in irradiated BM-MSCs after adipogenic 190 
induction (Figures 5D, 5E , 5F and 5H). However, knocking out Crif1 in BM-MSCs reduced 191 
both adipogenesis and RANKL expression (Figures 5C, 5D and 5F). OPG expression was not 192 
affected by Crif1 deletion or radiation treatment (Figures 5D and 5G). These data suggested 193 
that Crif1 mediates adipogenesis and RANKL secretion in adipocytes. 194 
Crif1 promotes RANKL secretion by modulating the cAMP/PKA signalling pathway 195 
To verify the mechanism underlying Crif1-mediated upregulation of RANKL expression, 196 
PKA agonist (forskolin) and inhibitor (H89) were added to the coculture system. Although 197 
RANKL expression and the RANKL/OPG ratio were both increased after treatment with 25 198 
µM forskolin, these effects were significantly weakened in Crif1 knockout BM-MSCs 199 
(Figures 6A, 6B, 6C and 6E). In addition, RANKL expression and the RANKL/OPG ratio 200 
were both decreased when Crif1-overexpressing BM-MSCs and controls were treated with 201 
20 µM H89 (Figures 6F, 6G , 6H and 6J). OPG expression was not affected by forskolin or 202 
H89 treatment (Figures 6A, 6D, 6F and 6H). The most TRAP-positive cells were found in the 203 
coculture with forskolin-treated BM-MSCs (Figures 6K and 6L), the fewest TRAP-positive 204 
cells were found in the coculture with H89-treated cells (Figures 6M and 6N). After the 205 
addition of forskolin, CREB phosphorylation was significantly increased in the control 206 
BM-MSCs, but was dramatically inhibited in Crif1 knockout BM-MCSs (Figure 6O). We 207 
also observed that CREB phosphorylation was suppressed in both Crif1-overexpressing 208 
BM-MSCs and controls following exposure to H89 (Figure 6P). These results demonstrated 209 
that Crif1 promotes RANKL expression through cAMP/PKA signalling pathway. 210 
Crif1 inhibitors effectively suppress RANKL secretion and CREB phosphorylation 211 
We used ClusPro and InterProSurf to investigate the interface in Crif1-PKAα complex, and 212 
results showed that Thr
197
, Gly
200
, Thr
201
, Glu
203
, and Phe
129
 of PKAα interact with Ile132, 213 
Met
128
, Ile
121
, His
120
, and Arg
117
 in the long alpha helical region of Crif1, forming the binding 214 
interface (Figure 7A). A virtual screening using 462,608 compounds from the Life Chemicals 215 
database around His
120
 of Crif1 was carried out using the program Autodock_vina. A set of 216 
13 compounds was selected for experimental screening based on binding energy <-12.0 217 
kcal/mol (Table S1). Initially a tetrazolium salt (WST-8) assay was carried out to study 218 
potential toxic effects of these compounds on hBM-MSCs, vero cells and mouse BM-MSCs 219 
(Figures S1-S3). The compounds F0382-0033, F3408-0076, F1430-0134, F3408-0031 and 220 
F1430-0130 showed low toxicity to hBM-MSCs at concentrations of 25 μM ( Figure 7G-7K). 221 
The binding pattern in these ligand−protein complexes potentially contained multiple 222 
interactions dominated by hydrophobic amino acids (Figure 7B-7F). To determine whether 223 
these 5 Crif1 inhibitors affected RANKL expression, hBM-MSCs were pretreated with these 224 
compounds followed by treatment with forskolin. ELISA analysis of supernatant medium 225 
revealed that RANKL expression was dramatically decreased by treatment with Crif1 226 
inhibitors (Figure 7L). OPG expression could be significantly increased by F1430-0134 227 
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(Figure 7M). Moreover, RANKL/OPG ratios were also decreased by these 5 inhibitors 228 
(Figure 7N). To further understand the mechanism, CREB phosphorylation was detected. 229 
Western blotting analysis showed that CREB phosphorylation was inhibited by treatment 230 
with the 5 inhibitors that showed suppressive effects on RANKL expression (Figure 7O). 231 
Discussion 232 
Radiation exposure (due to radiotherapy, accidental causes or terrorism) causes 233 
irreparable damage to tissues and organs such as bone marrow. It suppresses bone formation 234 
and elevates resorption, disturbing the balance between them and leading to a dramatic 235 
decline in trabecular bone(D'Oronzo, Stucci, Tucci, & Silvestris, 2015; Jia, Gaddy, Suva, & 236 
Corry, 2011). In this study, we treated mice with a single dose of 5 Gy to generate a model of 237 
radiation-induced osteoporosis. RANKL expression and RANKL/OPG ratios actually 238 
increased in the surviving bone marrow cells after radiation, which was consistent with a 239 
previous study(Alwood et al., 2015). Meanwhile, expression of Crif1 and bone resorption 240 
also increased, indicating a relationship between RANKL and Crif1 in osteoporosis. 241 
BM-MSCs, osteoblasts, adipocytes and activated T lymphocytes in bone marrow are the 242 
main source of RANKL secretion(Boyce & Xing, 2008; Honma et al., 2013); thus, to 243 
elucidate the possible role of Crif1 in RANKL expression, we generated bone marrow 244 
cell-specific Crif1-deficient mice. Conditional Crif1 deletion from bone marrow could reduce 245 
RANKL expression and relieve bone loss after radiation, suggesting that Crif1 is involved in 246 
RANKL expression and osteoporosis. 247 
BM-MSCs, which are a major and important component of the haematopoietic 248 
microenvironment, secrete soluble RANKL and OPG(Horowitz, Xi, Wilson, & Kacena, 2001; 249 
Morrison & Scadden, 2014). In our study, overexpression of Crif1 in BM-MSCs resulted in 250 
an increase in RANKL secretion, while deletion of Crif1 from BM-MSCs significantly 251 
reduced RANKL expression. BM-MSCs are pluripotent and are the progenitors of both bone 252 
marrow osteocytes and adipocytes. The balance between osteogenic and adipogenic 253 
differentiation of BM-MSCs also plays a pivotal role in maintaining bone homeostasis(Mori 254 
et al., 2014; Yue, Zhou, Shimada, Zhao, & Morrison, 2016). Excessive numbers of 255 
adipocytes are often found in the bone marrow of patients with osteoporosis. A recent study 256 
revealed that bone marrow adipocytes can also secrete RANKL and accelerate 257 
osteoclastogenesis(Fan et al., 2017). Moreover, after radiation exposure, the haematopoietic 258 
red marrow gradually turns to yellow, a phenomenon known as bone marrow fatting. 259 
Compared to other cells in bone marrow, BM-MSCs are more resistant to radiation; however, 260 
radiation impairs the balance between osteogenic and adipogenic differentiation of 261 
BM-MSCs, decreasing osteogenesis while increasing RANKL expression and 262 
adipogenesis(Cao et al., 2011). We previously reported that Crif1 can promote the 263 
adipogenesis of BM-MSCs. Here, we found that deletion of Crif1 from BM-MSCs can 264 
reduce both adipogenesis and RANKL expression. Osteogenesis and adipogenesis in the 265 
bone marrow are inversely correlated, so reduced adipogenesis results in an increase in the 266 
osteoblast pool(Muruganandan, Roman, & Sinal, 2009; Nuttall & Gimble, 2000). 267 
RANKL functions as an osteoclast-activating factor, and its binding to RANK induces 268 
the activation of transcription factors such as c-fos, NFAT, and nuclear factor kappa B 269 
(NF-κB) in preosteoclasts and initiates several downstream signalling pathways, especially 270 
the NF-κB pathway(Nakashima, Hayashi, & Takayanagi, 2012). RANKL expression can be 271 
upregulated by many agents, such as PTH and forskolin. Forskolin can stimulate RANKL 272 
expression through the cAMP/PKA signalling pathway(Kondo, Guo, & Bringhurst, 2002; 273 
Tseng et al., 2010). However, deletion of Crif1 from BM-MSCs impairs the promotion of 274 
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RANKL expression by forskolin. Moreover, overexpression of Crif1 in BM-MSCs does not 275 
increase RANKL expression upon exposure to a PKA inhibitor. Our previous study revealed 276 
that Crif1 can interact with PKA and promote adipogenesis. Here, we further demonstrated 277 
that Crif1 can also promote RANKL expression through the cAMP/PKA signalling pathway. 278 
Drugs for the treatment of osteoporosis could be divided into anabolic and antiresorptive 279 
categories. Bisphosphonates (including alendronate and ibandronate), oestrogen, selective 280 
oestrogen receptor modulators (SERMs), and denosumab are antiresorptive drugs, whereas 281 
parathyroid hormone (PTH) and its analogues are anabolic agents(Andreopoulou & Bockman, 282 
2015; Favus, 2010; Torstrick & Guldberg, 2014). However, the long-term adverse effects of 283 
these anti-osteoporotic drugs should be considered, such as hypocalcaemia, arthralgia, nausea, 284 
and especially the development of breast cancer and risks of cardiovascular events and 285 
thromboembolism associated with treatment with oestrogen and SERMs(Black & Rosen, 286 
2016; Khan, Cheung, & Khan, 2017). Therefore, it is necessary to look for new drugs with 287 
high efficiency but few side effects. Because of the importance of RANKL in osteoclast 288 
differentiation, RANKL-secreting cells, which play a central role in osteoclastogenesis, are 289 
the targets of most antiresorptive agents(Dempster, Lambing, Kostenuik, & Grauer, 2012; 290 
Tella & Gallagher, 2014). Future drug screening should target not only the regulation of the 291 
balance between bone formation and bone resorption but also the balance between osteogenic 292 
and adipogenic differentiation. Here, through screening, we identified five compounds that 293 
effectively inhibit Crif1 activity in the cAMP/PKA signalling pathway. These five 294 
compounds may have dual actions on bone metabolism, both increasing bone formation and 295 
decreasing bone resorption and adipogenesis. 296 
In summary, we demonstrated that Crif1 plays a crucial role in osteoporosis and that 297 
conditional Crif1 deletion reduces bone loss after radiation. Moreover, through screening, we 298 
identified five Crif1 inhibitors that could dramatically reduce RANKL secretion and CREB 299 
phosphorylation. This study enriches current knowledge of the pathogenesis of 300 
radiation-induced osteoporosis and provides insights into potential therapeutic strategies for 301 
osteoporosis treatment. 302 
Materials and Methods 303 
Mouse Strains 304 
Male and female C57BL/6 mice (aged 12-14 weeks) were purchased from Beijing HFK 305 
Bio-Technology Co. Ltd. B6.129P2-Lyz2tm1(cre)/Nju mice were received as a gift from 306 
Assistant Professor Tao Wang (Third Military Medical University). Crif
fl/fl 
mice were 307 
constructed by Nanjing BioMedical Research Institute of Nanjing University (NBRI). 308 
Lyz2Cre;Crif1
fl/fl 
mice were generated by crossing Crif
fl/fl 
mice to 309 
B6.129P2-Lyz2tm1(cre)/Nju transgenic mice. For radiation treatment, mice were irradiated 310 
with 5 Gy Co-60 at a rate of 0.69 Gy/minute. Blood was collected at 7 days after irradiation, 311 
and serum from each mouse was analysed individually in triplicate.  312 
Cell culture and treatment 313 
For in vitro study, mouse bone marrow mesenchymal stem/stromal cells (BM-MSCs) 314 
purchased from Cyagen Biosciences were cultured in mouse mesenchymal stem cell medium 315 
(MUCMX-90011, Cyagen Biosciences) at 37℃ and 5% CO2. For radiation treatment, mouse 316 
BM-MSCs were irradiated with 9 Gy Co-60 at a rate of 0.69 Gy/minute. 317 
RAW264.7 cells were cultured in Dulbecco’s modified Eagle medium (DMEM, HyClone) 318 
supplemented with 10% FBS. 319 
For osteoclast induction, RAW264.7 cells and mouse BM-MSCs were cocultured in a 320 
12-well transwell unit (0.4 µm) for 7 days with or without forskolin (25 µM) or H89 (20 µM) 321 
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treatment. After 7 days of coculture, cells were collected for RT-qPCR and Western blotting; 322 
meanwhile, supernatant medium was collected for ELISA. 323 
Human bone marrow mesenchymal stem/stromal cells (hBM-MSCs) (catalogue No. 7500, 324 
ScienCell) were cultured in mesenchymal stem cell medium (catalogue No. 7501, ScienCell) 325 
at 37 ℃ and 5% CO2. 326 
Crif1 knockout and overexpression in vitro 327 
For Crif1 overexpression, mouse BM-MSCs were transfected with a Crif1 lentiviral 328 
overexpression vector (pLV[Exp]-EGFP:T2A:Puro-EF1A>mGadd45gip1 329 
[NM_183358.4]) constructed by Cyagen Biosciences (vector ID: VB180112-1182ypt) and 330 
selected with 5 µg/ml puromycin dihydrochloride (A1113803, Invitrogen). An empty vector 331 
(pLV[Exp]-EGFP:T2A:Puro-Null, vector ID: VB160420-1011mqh, Cyagen Biosciences) was 332 
included as a control. 333 
For Crif1 knockout, mouse BM-MSCs were first transfected with lentiCas9-Blast vector 334 
(Genomeditech) and selected with 5 µg/ml blasticidin S HCl (A1113903, Invitrogen). Then, 335 
cells were transfected with CRISPR/Cas9 M_Gadd45gip1 gRNA vector (target sequence: 336 
GCGGGGGCGCACGGTAGCTG, Genomeditech) and selected with 5 µg/ml puromycin 337 
dihydrochloride. An empty vector (LentiGuide-Puro-Scramble-gRNA, Genomeditech) was 338 
included as a control. 339 
In vitro adipogenic differentiation 340 
To induce adipogenesis, mouse BM-MSCs were treated in mouse mesenchymal stem cell 341 
adipogenic differentiation medium (MUCMX-90031, Cyagen Biosciences). After 342 
differentiation, we preserved the supernatant medium for ELISA and fixed the cells 343 
with 2 ml of 4% formaldehyde solution for 30 minutes. Then, the cells were stained with 1 344 
ml oil red O working solution (catalogue No. S0131, Cyagen Biosciences) for 30 minutes and 345 
visualized with a light microscope (Leica DMIRB, Heidelberg, Germany). The dye from oil 346 
red O staining was extracted using isopropanol, and the optical density at 510 nm was 347 
measured using a Varioskan FLASH microplate reader. 348 
Micro-CT analysis 349 
Femurs were dissected, fixed overnight in 4% paraformaldehyde, and stored in 1% 350 
paraformaldehyde at 4℃. Trabecular bone parameters were measured in the distal metaphysis 351 
of the femur. We started analysing slices at the bottom of the distal growth plate, where the 352 
epiphyseal cap structure completely disappeared and continued for 95 slices (10.5 µm/slice, 353 
using SCANCO VivaCT40) towards the proximal end of the femur. 354 
Isolation of bone marrow cells  355 
Femurs were collected and cleaned in sterile PBS, and both ends of each femur were trimmed 356 
off. Bones were placed in a 0.6-mL microcentrifuge tube that was cut open at the bottom and 357 
nested inside a 1.5-mL microcentrifuge tube. Fresh bone marrow was spun out by brief 358 
centrifugation (from 0 to 10,000 rpm, 9 s). Red blood cells were lysed using RBC lysis buffer 359 
(catalogue NO. RT122-02, TIANGEN). After centrifugation (3,000 rpm, 5 minutes), cells at 360 
the bottom layer were collected for Western blotting and RT-qPCR assays(Fan et al., 2017). 361 
Western blotting and antibodies 362 
Protein expression in the samples was analysed by Western blotting. Total protein lysates 363 
were extracted with cell lysis buffer for Western blotting and immunoprecipitation (catalogue 364 
No. P0013, Beyotime) and denatured by boiling. Protein samples were resolved on 12% 365 
SDS-polyacrylamide gels and transferred to polyvinylidene fluoride membranes (PVDF 366 
Western Blotting Membranes; Roche). Membranes were blocked in PBS containing 5% (w/v) 367 
nonfat dry milk and 0.1% TWEEN 20 and then incubated with the appropriate primary 368 
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antibodies overnight at 4°C. Membranes were washed with TBST three times, and then 369 
incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies for 1 370 
h at 24°C. Immunoreactive bands were detected by the BeyoECL Plus reagent (P0018, 371 
Beyotime) using a Photo-Image System (Molecular Dynamics, Sunnyvale, CA, USA). The 372 
primary antibodies used for blotting were as follows: Crif1 (M-222) (sc-134882; Santa Cruz), 373 
RANK (H-7) (sc-374360; Santa Cruz), A-FABP (AP2, sc-18661; Santa Cruz), PPARγ 374 
(sc-7273; Santa Cruz), β-actin (sc-47778; Santa Cruz), phospho-CREB rabbit mAb (#9198; 375 
Cell Signaling Technology), and CREB rabbit mAb (#9197; Cell Signaling Technology). 376 
RT-qPCR 377 
Real-time quantitative polymerase chain reaction (RT-qPCR) was used to analyse the mRNA 378 
levels of selected genes in collected samples. Total RNA was extracted using TRIzol Reagent 379 
(catalogue No. 10296010, Invitrogen) according to the manufacturer’s instructions. 380 
First-strand cDNA was synthesized from l µg of RNA using the PrimeScript RT Reagent Kit 381 
with gDNA Eraser (catalogue No. RR047A, TaKaRa). qPCR was performed in triplicate in 382 
20-µl reactions containing SYBR Premix Ex Taq II (catalogue No. RR820A, TaKaRa). The 383 
reaction protocol was as follows: heating for 30 s at 95℃, followed by 40 cycles of 384 
amplification (5 s at 95℃, 30 s at 60℃). 385 
The sequences of the RT-PCR primers were as follows: 386 
M-actin-F: AGCCATGTACGTAGCCATCC,  387 
M-actin-R: CTCAGCTGTGGTGGTGAA, 388 
M-Rankl-F: GCTCCGAGCTGGTGAAGAAA, 389 
M-Rankl-R:CCCCAAAGTACGTCGCATCT, 390 
M-OPG-F: GTTCCTGCACAGCTTCACAA,  391 
M-OPG-R: AAACAGCCCAGTGACCATTC. 392 
ELISA 393 
The concentrations of RANKL and OPG were measured using the Mouse RANκL (Receptor 394 
Activator of Nuclear Factor Kappa B Ligand) ELISA Kit (E-EL-M0644c, elabscience), 395 
Human sRANKL (Soluble Receptor Activator of Nuclear factor-kB Ligand) ELISA Kit 396 
(E-EL-H5558c, elabscience), Mouse OPG (Osteoprotegerin) ELISA Kit (E-EL-M0081c, 397 
elabscience) and Human OPG (Osteoprotegerin) ELISA Kit (E-EL-H1341c, elabscience) 398 
according to the manufacturer’s instructions. Assays were performed in triplicate. 399 
Tartrate-resistant acid phosphatase (TRAP) staining 400 
After the 7-day coculture period, cells were washed once with PBS, fixed in 10% formalin 401 
for 10 minutes, and incubated with a substrate solution, naphthol AS-BI phosphate (catalogue 402 
No. 387, Sigma), in the presence of 50 mM sodium tartrate at 37 °C for 1 h. The resulting 403 
mononuclear and multinuclear TRAP-positive cells were visualized by light microscopy and 404 
quantified. 405 
Histochemistry and histomorphometric analysis 406 
Femurs were dissected, fixed overnight in 4% paraformaldehyde, decalcified in 10% EDTA 407 
(pH 7.0) for 20 days and embedded in paraffin. Longitudinally oriented sections of bone 4 408 
μm thick, including the metaphysis and diaphysis, were processed for histochemistry and 409 
haematoxylin and eosin (H&E) staining. Dewaxed sections were also stained for 410 
tartrate-resistant acid phosphatase (TRAP) activity to identify osteoclasts. Sections were 411 
incubated in TRAP stain for 45 minutes at 37℃. 412 
Crif1 inhibitor screening 413 
ClusPro and InterProSurf were used to investigate the interface in Crif1-PKAα complex. A 414 
virtual screening using 462,608 compounds from the Life Chemicals database around His
120
 415 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/725408doi: bioRxiv preprint first posted online Aug. 5, 2019; 
10 
 
of Crif1 was carried out using the program Autodock_vina. For inhibitor screening, 416 
hBM-MSCs were cultured in 6-well plates and pretreated with 5 different compounds (25 417 
µM). After 3 hours of pretreatment, forskolin (25 µM) was added to the medium. After 1 418 
hour of forskolin treatment, total protein lysates were extracted for CREB phosphorylation 419 
detection, and 3 days later, supernatant medium was collected for ELISA. 420 
Tetrazolium salt (WST-8) assay  421 
A tetrazolium salt (WST-8) assay was carried out to study the toxicity of compounds to 422 
hBM-MSCs. hBM-MSCs seeded at a density of 3000 cells per well in 96-well plate were 423 
treated with 5 different compounds at 8 final concentrations (3.125µM, 6.25µM, 12.5µM, 424 
25µM, 50µM, 100µM, 200µM, 400µM). Three days later, 10µl cell counting kit-8 solution 425 
was added to each well. After 4 hours of incubation, the absorbance at 450 nm was measured 426 
using a Varioskan FLASH microplate reader (Thermo). 427 
Statistical analysis 428 
The mRNA expression levels of RANKL and OPG in the tested samples were determined as 429 
the cycle threshold (CT) level, and normalized copy numbers (relative quantification) were 430 
calculated using the △△CT equation as follows: △△CT=△CT of the bone marrow sample 431 
-△CT of β-actin, and then the normalized copy number (relative quantification)=2-△△CT. Data 432 
are presented as the mean±SD. Statistical significance was assessed using a two-tailed paired 433 
Student’s t-test. The results were considered significant when * p<0.05 or ** p<0.01. 434 
Study approval 435 
All animal studies performed were approved by the Institutional Animal Care and Use 436 
Committee at the Third Military Medical University. 437 
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Figures: 601 
 602 
Figure 1. Radiation induces osteoporosis in mice 603 
(A) Micro-CT images of the distal metaphysis of the femur. 604 
(B-H) Micro-CT analysis of the trabecular bone volume/total volume (B), connectivity 605 
density (C), trabecular number (D), bone mineral density (E), trabecular thickness (F), 606 
trabecular spacing (G), and structure model index (H). 607 
(I) H&E staining of femoral sections from irradiated mice and controls. 608 
(J) TRAP staining of femoral sections from irradiated mice and controls. 609 
(K) RT-qPCR analysis of RANKL and OPG mRNA expression in flushed whole bone 610 
marrow. 611 
(L) RANKL/OPG ratio of RT-qPCR results. 612 
(M) Western blotting analysis of Crif1 expression in flushed whole bone marrow. 613 
*P < 0.05, **P < 0.01. All experiments were performed in triplicate, and the bars represent 614 
the mean ± SD. 615 
 616 
 617 
 618 
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 619 
Figure 2. Conditional Crif1 deletion from bone marrow reduces bone loss after 620 
radiation 621 
(A) Histochemical staining analysis of Crif1 expression in femoral bone marrow. 622 
(B) RT-qPCR analysis of RANKL and OPG mRNA expression in flushed whole bone 623 
marrow of Crif1
fl/fl 
mice and Lyz2Cre;Crif1
fl/fl 
mice after 5 Gy radiation. 624 
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(C) RANKL/OPG ratio of RT-qPCR results. 625 
(D) Micro-CT images of the distal metaphysis of the femur from Lyz2Cre;Crif1
fl/fl 
mice and 626 
Crif1
fl/fl 
mice. 627 
(E-K) Micro-CT analysis of the trabecular bone volume/total volume (E), connectivity 628 
density (F), trabecular number (G), bone mineral density (H), trabecular thickness (I), 629 
trabecular spacing (J), and structure model index (K). 630 
(L) H&E staining of femoral sections from Crif1
fl/fl 
mice and Lyz2Cre;Crif1
fl/fl 
mice. 631 
(M) TRAP staining of femoral sections from Crif1
fl/fl 
mice and Lyz2Cre;Crif1
fl/fl 
mice. 632 
*P < 0.05, **P < 0.01. All experiments were performed in triplicate, and the bars represent 633 
the mean ± SD. 634 
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 658 
 659 
 660 
Figure 3. Overexpression of Crif1 in BM-MSCs results in increases in RANKL secretion 661 
and the ratio of RANKL to OPG 662 
(A) Western blotting analysis of Crif1 expression in mouse BM-MSCs. Mouse BM-MSCs 663 
were transfected with a Crif1 lentiviral overexpression vector. 664 
(B) RT-qPCR analysis of RANKL and OPG mRNA expression in BM-MSCs and 665 
Crif1-overexpressing BM-MSCs (OV). BM-MSCs and OV were cocultured with RAW264.7. 666 
(C) RANKL/OPG ratio of RT-qPCR results. 667 
(D) ELISA analysis of RANKL protein levels in coculture supernatant medium.  668 
(E) ELISA analysis of OPG protein levels in coculture supernatant medium.  669 
(F) RANKL/OPG ratio in coculture supernatant medium. 670 
(G) TRAP staining of RAW264.7 after 7 days in coculture. 671 
(H) Average number of TRAP-positive cells/well (arrow) from RAW264.7 cells in coculture.  672 
*P < 0.05, **P < 0.01. All experiments were performed in triplicate, and the bars represent 673 
the mean ± SD. 674 
 675 
 676 
 677 
 678 
 679 
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 680 
 681 
Figure 4. Crfi1 is involved in the regulation of RANKL expression after radiation 682 
(A) Western blotting analysis of Crif1 and RANK expression in RAW264.7 cells. Crif1 was 683 
knocked out from RAW264.7 cells (RAW264.7-KO). 684 
(B) TRAP staining of RAW264.7-KO and controls after 7 days in coculture with mouse 685 
BM-MSCs. 686 
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(C) Average number of TRAP-positive cells/well (arrow) from RAW264.7-KO and controls 687 
after 7 days in coculture with mouse BM-MSCs. 688 
(D) Western blotting analysis of Crif1 expression in BM-MSCs. Crif1 was knocked out from 689 
mouse BM-MSCs (KO), and KO and controls were irradiated with 9 Gy Co-60. 690 
(E) RT-qPCR analysis of RANKL and OPG mRNA expression in BM-MSCs and Crif1 691 
knockout BM-MSCs (KO). BM-MSCs and KO were cocultured with RAW264.7  692 
(F) RANKL/OPG ratio of RT-qPCR results. 693 
(G) ELISA analysis of RANKL protein levels in coculture supernatant medium.  694 
(H) ELISA analysis of OPG protein levels in coculture supernatant medium.  695 
(I) RANKL/OPG ratio in coculture supernatant medium. 696 
(J) TRAP staining of RAW264.7 after 7 days in coculture. 697 
(K) Average number of TRAP-positive cells/well (arrow) from RAW264.7 in coculture. 698 
*P < 0.05, **P < 0.01. All experiments were performed in triplicate, and the bars represent 699 
the mean ± SD. 700 
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 721 
Figure 5. Crif1 mediates adipogenesis and RANKL secretion in adipocytes 722 
(A) Oil red O staining analysis of mouse BM-MSCs after 21 days of adipogenic 723 
differentiation. Crif1 was knocked out from mouse BM-MSCs (KO), and KO and controls 724 
were irradiated with 9 Gy Co-60. KO and controls were treated with mouse mesenchymal 725 
stem cell adipogenic differentiation medium (Ad) to induce adipogenesis. 726 
(B) The dye from oil red O staining was extracted using isopropanol, and the optical density 727 
at 510 nm was measured using a Benchmark Plus. 728 
(C) Western blotting analysis of adipogenesis-related markers and transcription factors 729 
PPARγ and AP2 in mouse BM-MSCs after 21 days of adipogenic differentiation. 730 
(D) RT-qPCR analysis of RANKL and OPG mRNA expression in BM-MSCs and Crif1 731 
knockout BM-MSCs (KO).  732 
(E)RANKL/OPG ratio of RT-qPCR results. 733 
(F) ELISA analysis of RANKL protein levels in supernatant adipogenic differentiation 734 
medium. 735 
(G) ELISA analysis of OPG protein levels in supernatant adipogenic differentiation medium.  736 
(H) RANKL/OPG ratio in supernatant adipogenic differentiation medium.  737 
*P < 0.05, **P < 0.01..All experiments were performed in triplicate, and the bars represent 738 
the mean ± SD. 739 
 740 
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 741 
Figure 6. Crif1 promotes RANKL secretion by modulating the cAMP/PKA signalling 742 
pathway 743 
(A) RT-qPCR analysis of RANKL and OPG mRNA expression in BM-MSCs and Crif1 744 
knockout BM-MSCs (KO). BM-MSCs and KO were cocultured with RAW264.7 with or 745 
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without 25 µM forskolin respectively. 746 
(B) RANKL/OPG ratio of RT-qPCR results.  747 
(C) ELISA analysis of RANKL protein levels in coculture supernatant medium with or 748 
without 25 µM forskolin.  749 
(D) ELISA analysis of OPG protein levels in coculture supernatant medium with or without 750 
25 µM forskolin.  751 
(E) RANKL/OPG ratio in coculture supernatant medium with or without 25 µM forskolin.  752 
(F) RT-qPCR analysis of RANKL and OPG mRNA expression in BM-MSCs and 753 
Crif1-overexpressing BM-MSCs (OV). BM-MSCs and OV were cocultured with RAW264.7 754 
with or without 20 µM H89 respectively. 755 
(G) RANKL/OPG ratio of RT-qPCR results.  756 
(H) ELISA analysis of RANKL protein levels in coculture supernatant medium with or 757 
without 20 µM H89. 758 
(I) ELISA analysis of OPG protein levels in coculture supernatant medium with or without 20 759 
µM H89. 760 
(J) RANKL/OPG ratio in coculture supernatant medium with or without 20 µM H89.  761 
(K) TRAP staining of RAW264.7 in coculture treated with or without 25 µM forskolin.  762 
(L) Average number of TRAP-positive cells/well (arrow) from RAW264.7 in coculture 763 
treated with or without 25 µM forskolin.  764 
(M) TRAP staining of RAW264.7 in coculture treated with or without 20 µM H89. 765 
(N) Average number of TRAP-positive cells/well (arrow) from RAW264.7 in coculture 766 
treated with or without 20 µM H89. 767 
(O) Western blotting analysis of CREB phosphorylation levels in BM-MSCs in coculture 768 
treated with or without 25 µM forskolin. 769 
(P) Western blotting analysis of CREB phosphorylation levels in BM-MSCs in coculture 770 
treated with or without 20 µM H89. 771 
*P < 0.05, **P < 0.01..All experiments were performed in triplicate, and the bars represent 772 
the mean ± SD. 773 
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 774 
 775 
 776 
Figure 7. Crif1 inhibitors effectively suppress RANKL secretion and CREB 777 
phosphorylation 778 
(A) Crif1− PKAα interaction model showing Crif1 (colored in rose red) and PKAα (colored 779 
in cyan). Interface amino acids are shown as sticks and colored in rose red (for Crif1) and 780 
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cyan (for PKAα) and indicated as a zoomed-in view in the inset figure.  781 
(B-F) Chemical structure of each inhibitor molecule and their docked pose on Crif1 (colored 782 
in rose red, surface view). Docked molecule (stick) and the amino acids involved in the 783 
hydrophobic interactions (light purple) are shown. F0382-0033 (B), F3408-0076 (C), 784 
F1430-0134 (D), F3408-0031 (E) and F1430-0130 (F). 785 
(G-K) A tetrazolium salt (WST-8) assay was carried out to study the toxity effect of 786 
compounds on the hBM-MSCs. F0382-0033 (G), F3408-0076 (H), F1430-0134 (I), 787 
F3408-0031 (J) and F1430-0130 (K). 788 
(L) ELISA analysis of RANKL protein levels in supernatant medium. hBM-MSCs were 789 
pretreated with 5 different compounds followed by treatment with forskolin, and supernatant 790 
medium was collected for ELISA after 3 days. 791 
(M) ELISA analysis of OPG protein levels in supernatant medium. 792 
(N) RANKL/OPG ratio in supernatant medium. 793 
(O) Western blotting analysis of CREB phosphorylation levels. hBM-MSCs were pretreated 794 
with 5 different compounds followed by treatment with forskolin and total protein lysates 795 
were extracted for CREB phosphorylation detection after 1 hour. 796 
*P < 0.05, **P < 0.01. All experiments were performed in triplicate, and the bars represent 797 
the mean ± SD. 798 
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Supplementary data 828 
 829 
 830 
Compound Name Affinity (kcal/mol) 
F3408-0076 -14.6 
F0382-0033 -13.1 
F1430-0130 -12.9 
F0808-0153 -12.5 
F0808-0131 -12.5 
F0808-0151 -12.4 
F0808-1181 -12.4 
F0808-1175 -12.4 
F1269-0120 -12.3 
F0808-0152 -12.2 
F3408-0031 -12.2 
F1430-0134 -12 
F1430-0138 -12 
 831 
 832 
Table S1. 13 compounds were chosen based on binding energy <-12.0 kcal/mol. 833 
 834 
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 835 
 836 
Figure S1. A tetrazolium salt (WST-8) assay was carried out to study the toxic effects of 837 
compounds on H –BM-MSCs. 838 
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 848 
 849 
Figure S2. A tetrazolium salt (WST-8) assay was carried out to study the toxic effects of 850 
compounds on vero cells. 851 
 852 
 853 
 854 
 855 
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 857 
 858 
Figure S3. A tetrazolium salt (WST-8) assay was carried out to study the toxic effects of 859 
compounds on mouse BM-MSCs. 860 
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